This issue's editor's favorite is Wang and colleagues “18F-MFBG PET/CT Is an Effective Alternative of 68Ga-DOTATATE PET/CT in the Evaluation of Metastatic Pheochromocytoma and Paraganglioma."
They state that the functional imaging choice for the evaluation of metastatic pheochromocytoma and paraganglioma is 68Ga-DOTATATE PET/CT as compared with MIBG imaging. 18F–meta-fluorobenzylguanidine (18F-MFBG) is a new PET tracer analog of meta-iodobenzylguanidine (MIBG).
The authors prospectively compared 18F-MFBG and 68Ga-DOTATATE PET/CT in 28 patients with metastatic PPGL. All patients underwent both 18F-MFBG and 68Ga-DOTATATE PET/CT studies within 1 week. Detected lesion numbers were compared.
18F-MFBG PET/CT was positive for metastases in all participants, while 68Ga-DOTATATE PET/CT was positive in 27 (96.4%). A total of 686 foci were detected by both 18F-MFBG and 68Ga-DOTATATE imaging. , while 33 additional foci were only detected by 18F-MFBG, whereas 16 foci were only shown on 68Ga-DOTATATE PET/CT.
The investigators concluded that 18F-MFBG PET/CT is effective in the evaluation of metastatic pheochromocytoma and paraganglioma and could be an alternative for 68Ga-DOTATATE PET/CT in this clinical setting.